gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1543Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГОВ, ГЕПАТОЛОГОВNATIONAL COLLEGE OF GASTROENTEROLOGISTS, HEPATOLOGISTSГастроэзофагеальная рефлюксная болезнь и функциональные заболевания желудочно-кишечного тракта: есть ли какая-то связь?Gastroesophageal reflux disease and the functional diseases of gastro-intestinal tract: are there any interrelations?ШептулинА. А.SheptulinA. A.Визе-ХрипуноваМ. А.Vize-KhripunovaM. A.2010300820102044448Copyright © Шептулин А.А., Визе-Хрипунова М.А., 20102010Шептулин А.А., Визе-Хрипунова М.А.Sheptulin A.A., Vize-Khripunova M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1543

Цель обзора. Обсудить возможную связь гастроэзофагеальной рефлюксной болезни (ГЭРБ) и других функциональных заболеваний желудочнокишечного тракта (ЖКТ) и показать, какие формы ГЭРБ можно рассматривать с позиций функциональной патологии.Полученные данные. Показано, что ГЭРБ часто сочетается с функциональной диспепсией и синдромом раздраженного кишечника. Это может быть обусловлено общностью патофизиологических механизмов данных заболеваний. В рамках неэрозивной формы ГЭРБ можно выделить 2 подгруппы больных, у которых: 1) отмечается связь клинических симптомов с эпизодами физиологического гастроэзофагеального рефлюкса (ГЭР) – больные с гиперсенситивным пищеводом или 2) эти клинические симптомы вообще не связаны с ГЭР – пациенты с функциональной изжогой и которые можно трактовать в рамках функциональной патологии. Для оптимизации диагностики и лечения этих форм ГЭРБ необходимы дальнейшие исследования.Заключение. В рамках ГЭРБ существуют формы заболевания, которые можно рассматривать с позиций функциональных расстройств ЖКТ.

The aim of review

The aim of review. To discuss possible relation of gastroesophageal reflux disease (GERD) and other functional diseases of gastro-intestinal tract (GIT) and demonstrate, which forms of GERD can be taken into account from the standpoints of functional diseases.

Received data

Received data. It is shown, that the GERD is frequently combined with functional dyspepsia and irritable bowel syndrome. It can be caused by common pathophysiological mechanisms of these diseases. Within the framework of non-erosive form of GERD it is possible to define 2 subgroups of patients, at which: 1)correlation of clinical symptoms to episodes of physiological gastroesophageal reflux (GER) is present – patients with hypersensitive esophagus or 2) clinical symptoms are not related to GER at all – patients with functional heartburn, which can be considered within the framework of functional pathology. Further studies are necessary to improve diagnostics and treatment of these forms of GERD.

Conclusion

Conclusion. Within the framework of GERD there are forms of disease which can be assessed from positions of functional disorders of GIT.

гастроэзофагеальная рефлюксная болезньфункциональная диспепсиясиндром раздраженного кишечникаgastroesophageal reflux diseasefunctional dyspepsiairritable bowel syndromeReferencesAgreus L., Svardsudd K., Nyren O. et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. – Gastroenterology. – 1995. – Vol. 109. – P. 671–680.Agreus L., Svardsudd K., Nyren O. et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. – Gastroenterology. – 1995. – Vol. 109. – P. 671–680.Armstrong D. Symptom assessment: methods and content // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 184–192.Armstrong D. Symptom assessment: methods and content // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 184–192.Broekaert D., Fischler B., Sifrim D. et al. Influence of citalapram, a selective serotonin reuptake inhibitor on esophageal hypersensitivity: a double-blind, placebo-controlled study // Aliment. Pharmacol. Ther. – 2006. – Vol. 23. – P. 365–370.Broekaert D., Fischler B., Sifrim D. et al. Influence of citalapram, a selective serotonin reuptake inhibitor on esophageal hypersensitivity: a double-blind, placebo-controlled study // Aliment. Pharmacol. Ther. – 2006. – Vol. 23. – P. 365–370.Erkrankungen der Verdauungsorgane / bearb. von G.V. Bergmann et al. – 1. Teil. – Berlin: Springer Verlag, 1926. – 1051 s.Erkrankungen der Verdauungsorgane / bearb. von G.V. Bergmann et al. – 1. Teil. – Berlin: Springer Verlag, 1926. – 1051 s.Fass R., Tougas G. Functional heartburn: the stimulus, the pain and the brain. – Gut. – 2002. – Vol. 51. – P. 885–892.Fass R., Tougas G. Functional heartburn: the stimulus, the pain and the brain. – Gut. – 2002. – Vol. 51. – P. 885–892.Focca R., Riddell R., Takubo K. Microscopic esophagitis: interobserver consistency using consensus-based criteria // Gut. – 2007. – Vol. 56 (suppl. III). – P. 75.Focca R., Riddell R., Takubo K. Microscopic esophagitis: interobserver consistency using consensus-based criteria // Gut. – 2007. – Vol. 56 (suppl. III). – P. 75.Galmiche J.P., Clouse R.E., Balint A. et al. Functional esophageal disorders // Gastroenterology. – 2006. – Vol. 130. – P. 1459–1465.Galmiche J.P., Clouse R.E., Balint A. et al. Functional esophageal disorders // Gastroenterology. – 2006. – Vol. 130. – P. 1459–1465.Goldkind L. Meeting expectations in FD: clinical and regulatory objectives. Regulatory viewpoint // Functional dyspepsia: current evidence and cutting edge outcomes . – Abstract book. – Montreal, 2005. – P. 19.Goldkind L. Meeting expectations in FD: clinical and regulatory objectives. Regulatory viewpoint // Functional dyspepsia: current evidence and cutting edge outcomes . – Abstract book. – Montreal, 2005. – P. 19.Heading R.C. Complete remission in GERD: dream or reality // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 198–101.Heading R.C. Complete remission in GERD: dream or reality // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 198–101.Hunt R.H., Tytgat G., Malfertheiner P. et al. Whistler consensus // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 47–50.Hunt R.H., Tytgat G., Malfertheiner P. et al. Whistler consensus // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 47–50.Locke G.R., Zinsmeister A.R., Fett S.L. et al. Overlap of gastrointestinal symptom complexes in a US community // Neurogastroenterol. Motil. – 2005 – Vol. 17.Locke G.R., Zinsmeister A.R., Fett S.L. et al. Overlap of gastrointestinal symptom complexes in a US community // Neurogastroenterol. Motil. – 2005 – Vol. 17.– P. 29–34.– P. 29–34.Malfertheiner P., Mönkemüller K., Wex T. GERD: endoscopic assesment: a reconcillation with symptoms // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 193–197.Malfertheiner P., Mönkemüller K., Wex T. GERD: endoscopic assesment: a reconcillation with symptoms // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 193–197.McQuaid K.R. Dyspepsia // Sleisenger and Fordtran’s gastrointestinal and liver disease / Ed. M. Feldman et al. 7th– ed. – Philadelphia–London–Toronto–Montreal– Sydney–Tokyo, 2002. – P. 102–118.McQuaid K.R. Dyspepsia // Sleisenger and Fordtran’s gastrointestinal and liver disease / Ed. M. Feldman et al. 7th– ed. – Philadelphia–London–Toronto–Montreal– Sydney–Tokyo, 2002. – P. 102–118.Modlin I.M., Hunt R. Whistler meeting // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 45–46.Modlin I.M., Hunt R. Whistler meeting // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 45–46.Mőnnikes H., Schwan T., Sander P. Request as a potential tool for the assesment of treatment response in functional gastrointestinal disorders // Gut. – 2008. – Vol. 57 (suppl. II). – P. 322.Mőnnikes H., Schwan T., Sander P. Request as a potential tool for the assesment of treatment response in functional gastrointestinal disorders // Gut. – 2008. – Vol. 57 (suppl. II). – P. 322.Neumann N., Mönkemüller K., Fry L.C. Dilated intercellular spaces of esophageal epithelium in non-erosive and erosive reflux disease patients and appropriate controls // Gut. – 2007. – Vol. 56 (suppl. III). – P. 206.Neumann N., Mönkemüller K., Fry L.C. Dilated intercellular spaces of esophageal epithelium in non-erosive and erosive reflux disease patients and appropriate controls // Gut. – 2007. – Vol. 56 (suppl. III). – P. 206.Nunez-Rodriguez H., Miranda-Sivela A., Madrigal R. et al. Gastroesophageal reflux disease and psychological factors // Gut. – 2007. – Vol. 56 (suppl. III). – P. 206.Nunez-Rodriguez H., Miranda-Sivela A., Madrigal R. et al. Gastroesophageal reflux disease and psychological factors // Gut. – 2007. – Vol. 56 (suppl. III). – P. 206.QuigleyE.M.M.NERD,GERDandbeyond:aconsideration of the expanding spectrum of gastroesophageal reflux disease // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 175–180.QuigleyE.M.M.NERD,GERDandbeyond:aconsideration of the expanding spectrum of gastroesophageal reflux disease // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 175–180.Sarkar S. et al. Contribution of central sensitisation to the development of non-cardiac chest pain // Lancet. – 2000. – Vol. 356. – P. 1154–1159.Sarkar S. et al. Contribution of central sensitisation to the development of non-cardiac chest pain // Lancet. – 2000. – Vol. 356. – P. 1154–1159.Sarkar S., Thompson D.G., Woolf C.J. et al. Patients with chest pain and occult gastroesophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid supression // Am. J. Gastroenterol. – 2004. – Vol. 99. – P. 1998–2006.Sarkar S., Thompson D.G., Woolf C.J. et al. Patients with chest pain and occult gastroesophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid supression // Am. J. Gastroenterol. – 2004. – Vol. 99. – P. 1998–2006.Stanghellini V., Barbara G., Cogliandro R. Overlap between GERD and IBS: irrefutable but subtle // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 114–117.Stanghellini V., Barbara G., Cogliandro R. Overlap between GERD and IBS: irrefutable but subtle // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 114–117.Tack J. What are we feeling: motility and hypersensitivity in GERD // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 163–167.Tack J. What are we feeling: motility and hypersensitivity in GERD // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 163–167.Tack J., Talley N.J., Camilleri M. et al. Functional gastroduodenal disorders // Gastroenterology. – 2006. – Vol. 130. – P. 1466–1479.Tack J., Talley N.J., Camilleri M. et al. Functional gastroduodenal disorders // Gastroenterology. – 2006. – Vol. 130. – P. 1466–1479.Talley N.J. and the working team for functional gastroduodenal disorders. Functional gastroduodenal disorders // The functional gastrointestinal disorders. – Boston–New York–Toronto–London, 1994. – P. 71–113.Talley N.J. and the working team for functional gastroduodenal disorders. Functional gastroduodenal disorders // The functional gastrointestinal disorders. – Boston–New York–Toronto–London, 1994. – P. 71–113.Talley N.J., Zinsmeister A.R., Schleck C.D. et al. Dyspepsia and dysрepsia subgroups: a population-based study // Gastroenterology. – 1992. – Vol. 102. – P. 1259–1268.Talley N.J., Zinsmeister A.R., Schleck C.D. et al. Dyspepsia and dysрepsia subgroups: a population-based study // Gastroenterology. – 1992. – Vol. 102. – P. 1259–1268.Thomson A.B.R. ReQuest: pain, pH, pills and promises // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 81–86.Thomson A.B.R. ReQuest: pain, pH, pills and promises // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 81–86.Tytgat G.N.J. Gastroesophageal reflux disease // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 223–225.Tytgat G.N.J. Gastroesophageal reflux disease // J. Clin. Gastroenterol. – 2007. – Vol. 41 (suppl. 2). – P. 223–225.

The authors declare that there are no conflicts of interest present.